Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
- Conditions
- Exudative Age-related Macular Degeneration
- Registration Number
- NCT01404845
- Lead Sponsor
- Affordance
- Brief Summary
•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries. The macular pigment, composed of carotenoid derivatives (lutein and zeaxanthin), may play an important role in the occurrence of AMD. An increase in macular pigment following dietary supplementation with lutein and zeaxanthin could allow early treatment with such supplements in subjects with a high risk of AMD, and encourage them to change their eating habits.
•Primary outcome:
Comparative analysis of the density and evolution of the density of macular pigment:
* In patients without any retinal pathology who underwent cataract surgery 1 month previously
* In the non-exudative eye of patients with exudative AMD in one eye by analyzing the density and evolution of the density of macular pigment in the non-exudative eye
* Secondary outcomes:
Analysis of changes in macular pigment density after taking food supplements (Nutrof Total versus comparator):
* Time taken to reach the maximum plateau of macular pigment density (no increase in density between 2 measurements)
* Time taken to return to the baseline macular pigment density after cessation of supplementation
* Study design :
Pilot study -Prospective, randomised, double-masked, comparative, multicenter.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Not provided
Exclusion criteria related to the study:
- Intolerance to the tested product
- Change in fundus image
- Patients already taking Nutrof Total or similar supplements containing Lutein and Zeaxanthin
- Allergy to mydriatics
Exclusion criteria for ophthalmologic reasons:
o Ocular diseases or conditions whose presence might interfere with the measurement of optical density of macular pigment (e.g. cataract, diabetic retinopathy, optic atrophy, myopia> -6.5 Diopters)
Exclusion criteria for systemic reasons:
o Medical or surgical history, disorder or disease (e.g. severe organic disease, acute or chronic: liver disease, endocrine, neoplastic, hematologic, infectious diseases, severe psychiatric disorder, significant cardiovascular abnormalities, etc...) and / or aggravating factors or structural defect, considered as being inconsistent with the study by the investigator.
Exclusion criteria for general reasons:
- Inability of the patient to understand the study procedures and to give informed consent.
- Ward of court
- Patient not covered by the social security scheme
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Comparative analysis of macular pigment density 18 months Comparative analysis of macular pigment density in patients who underwent cataract operation 1 month ago, without retinal pathology and in patients with exudative AMD in one eye by analyzing the density and evolution of the density of macular pigment in the non-exudative eye.
Optical density (OD)parameters of the macular pigments measured by an objective reflectometry method based on a 30° field image acquired by the Visucam 200 or 500 of Zeiss :
Area : where macular pigments could be detected
Max OD/Mean OD/ Volume : Maximum value/Mean Value/Sum of all OD in the area
- Secondary Outcome Measures
Name Time Method Analysis of changes in macular pigment density 18 months Analysis of changes in macular pigment density after taking food supplements (Nutrof Total versus comparator):
* Time taken to reach the maximum plateau of macular pigment density (no increase in density between 2 measurements)
* Time taken to return to the baseline macular pigment density after cessation of supplementation
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Docteur Jean-Jacques Masella
🇫🇷Grenoble, France
Centre ophtalmologique Rabelais
🇫🇷Lyon, France
Docteur Jean-Jacques Masella🇫🇷Grenoble, France